Pharmaceutical

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease

Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.

Jul 4, 2024 - 04:00
Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease
Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.
Read the original article

Tags:

Previous Article

Left in limbo: When pharma halts rare disease research

Next Article

Deal on Cancer ADC Gets Canceled by Eisai and Bristol Myers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ascidian launches first-ever clinical study of RNA exon editor for vision loss

Ascidian launches first-ever clinical study of RNA exon...

Jan 29, 2024

Cell and gene therapy approvals drive paradigm change in manufacturing

Cell and gene therapy approvals drive paradigm change i...

Oct 14, 2024

Robert Winn: Without ‘high-touch’ strategies, cancer’s breakthroughs will increase disparities

Robert Winn: Without ‘high-touch’ strategies, cancer’s ...

Sep 6, 2023